Figure 1.

SLC25A18 expression in colorectal cancer (CRC) and indicates unfavorable clinicopathological characteristics and prognose. A, B. SLC25A18 mRNA levels in CRC tissue were lower than not only normal tissue in colon adenocarcinoma (COAD) (N_tumor = 275, N_normal = 41) and rectum adenocarcinoma (READ) (N_tumor = 92, N_normal = 10) subsets from TCGA and GTEx (N_normal = 318) database, but also in matched para-tumor tissues (N = 31). C, D. SLC25A18 exhibited low expression in individual colon and rectum adenocarcinoma stages compared to normal tissue samples. E, F. SLC25A18 expression is negatively related to some clinical characteristics such as age and pretreatment serum carcinoembryonic levels (CEA). G, H. CRC patients with low expression of SLC25A18 exhibited a shorter disease-free survival time after receiving a radical surgery treatment, especially for those people with right colon cancer according to a cohort from GSE14333.